

Ertugliflozin (< 5%) / Sitagliptin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
4.1	11.08.2025	2400339-00016	Date of first issue: 01.02.2018

SECTION 1: IDENTIFICATION

Product name : Ertugliflozin (< 5%) / Sitagliptin Formulation

Manufacturer or supplier's details

Company : MSD

Address : Building A - Level 1/26 Talavera Rd
Macquarie Park NSW, Australia 2113

Telephone : 1 800 033 461

Emergency telephone number : Poisons Information Centre: Phone 13 11 26

E-mail address : EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical

Restrictions on use : Not applicable

SECTION 2. HAZARDS IDENTIFICATION**GHS Classification**

Skin corrosion/irritation : Category 2

Serious eye damage/eye irritation : Category 1

GHS label elements

Hazard pictograms :



Signal word : Danger

Hazard statements : H315 Causes skin irritation.
H318 Causes serious eye damage.

Precautionary statements : **Prevention:**
P264 Wash skin thoroughly after handling.
P280 Wear protective gloves/ eye protection/ face protection.
Response:
P302 + P352 IF ON SKIN: Wash with plenty of water.
P305 + P351 + P338 + P310 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. Immediately call a POISON

Ertugliflozin (< 5%) / Sitagliptin Formulation

Version	Revision Date:	SDS Number:	Date of last issue:
4.1	11.08.2025	2400339-00016	14.04.2025
			Date of first issue: 01.02.2018

CENTER/ doctor.
P332 + P313 If skin irritation occurs: Get medical advice/ attention.
P362 + P364 Take off contaminated clothing and wash it before reuse.

Other hazards which do not result in classification

May form explosive dust-air mixture during processing, handling or other means.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
Sitagliptin Phosphate	654671-77-9	>= 30 -< 60
Cellulose	9004-34-6	>= 10 -< 30
Ertugliflozin	1210344-83-4	>= 3 -< 5
Magnesium stearate	557-04-0	< 10
Propyl 3,4,5-trihydroxybenzoate	121-79-9	< 1

SECTION 4. FIRST AID MEASURES

General advice	:	In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.
If inhaled	:	If inhaled, remove to fresh air. Get medical attention if symptoms occur.
In case of skin contact	:	In case of contact, immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.
In case of eye contact	:	In case of contact, immediately flush eyes with plenty of water for at least 15 minutes. If easy to do, remove contact lens, if worn. Get medical attention immediately.
If swallowed	:	If swallowed, DO NOT induce vomiting. Get medical attention if symptoms occur. Rinse mouth thoroughly with water.
Most important symptoms and effects, both acute and delayed	:	Causes skin irritation. Causes serious eye damage.
Protection of first-aiders	:	First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
Notes to physician	:	Treat symptomatically and supportively.

SECTION 5. FIREFIGHTING MEASURES

Ertugliflozin (< 5%) / Sitagliptin Formulation

Version	Revision Date:	SDS Number:	Date of last issue:
4.1	11.08.2025	2400339-00016	14.04.2025
			Date of first issue: 01.02.2018

- Suitable extinguishing media : Water spray
Alcohol-resistant foam
Carbon dioxide (CO₂)
Dry chemical
- Unsuitable extinguishing media : None known.
- Specific hazards during fire-fighting : Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.
Exposure to combustion products may be a hazard to health.
- Hazardous combustion products : Carbon oxides
Metal oxides
Oxides of phosphorus
- Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.
- Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

- Personal precautions, protective equipment and emergency procedures : Use personal protective equipment.
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
- Environmental precautions : Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.
- Methods and materials for containment and cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal.
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding

Ertugliflozin (< 5%) / Sitagliptin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
4.1	11.08.2025	2400339-00016	Date of first issue: 01.02.2018

certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

- | | | |
|-----------------------------|---|--|
| Technical measures | : | Static electricity may accumulate and ignite suspended dust causing an explosion.
Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres. |
| Local/Total ventilation | : | Use only with adequate ventilation. |
| Advice on safe handling | : | Do not get on skin or clothing.
Do not breathe dust.
Do not swallow.
Do not get in eyes.
Wash skin thoroughly after handling.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
Keep container tightly closed.
Minimize dust generation and accumulation.
Keep container closed when not in use.
Keep away from heat and sources of ignition.
Take precautionary measures against static discharges.
Take care to prevent spills, waste and minimize release to the environment. |
| Hygiene measures | : | If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.
When using do not eat, drink or smoke.
Contaminated work clothing should not be allowed out of the workplace.
Wash contaminated clothing before re-use.
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls. |
| Conditions for safe storage | : | Keep in properly labelled containers.
Keep tightly closed.
Store in accordance with the particular national regulations. |
| Materials to avoid | : | Do not store with the following product types:
Strong oxidizing agents |

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION**Components with workplace control parameters**

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Sitagliptin Phosphate	654671-77-9	TWA	0.6 mg/m3 (OEB 2)	Internal

Ertugliflozin (< 5%) / Sitagliptin Formulation

Version 4.1 Revision Date: 11.08.2025 SDS Number: 2400339-00016 Date of last issue: 14.04.2025
 Date of first issue: 01.02.2018

Cellulose	9004-34-6	TWA	10 mg/m3	AU OEL
		TWA	10 mg/m3	ACGIH
Ertugliflozin	1210344-83-4	TWA	10 µg/m3 (OEB 3)	Internal
		Wipe limit	100 µg/100 cm ²	Internal
Magnesium stearate	557-04-0	TWA	10 mg/m3	AU OEL
		TWA (Inhalable particulate matter)	10 mg/m3	ACGIH
		TWA (Respirable particulate matter)	3 mg/m3	ACGIH

Engineering measures : All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices). Minimize open handling.

Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type : Particulates type

Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Eye protection : Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection : Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : powder

Colour : No data available

Ertugliflozin (< 5%) / Sitagliptin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
4.1	11.08.2025	2400339-00016	Date of first issue: 01.02.2018

Odour	:	No data available
Odour Threshold	:	No data available
pH	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	Not applicable
Evaporation rate	:	Not applicable
Flammability (solid, gas)	:	May form explosive dust-air mixture during processing, handling or other means.
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapour pressure	:	Not applicable
Relative vapour density	:	Not applicable
Relative density	:	No data available
Density	:	No data available
Solubility(ies) Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	Not applicable
Auto-ignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity Viscosity, kinematic	:	Not applicable
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.
Molecular weight	:	No data available

Ertugliflozin (< 5%) / Sitagliptin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
4.1	11.08.2025	2400339-00016	Date of first issue: 01.02.2018

Particle characteristics
Particle size : No data available

SECTION 10. STABILITY AND REACTIVITY

Reactivity	: Not classified as a reactivity hazard.
Chemical stability	: Stable under normal conditions.
Possibility of hazardous reactions	: May form explosive dust-air mixture during processing, handling or other means. Can react with strong oxidizing agents.
Conditions to avoid	: Heat, flames and sparks. Avoid dust formation.
Incompatible materials	: Oxidizing agents
Hazardous decomposition products	: No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION

Exposure routes	: Inhalation Skin contact Ingestion Eye contact
-----------------	--

Acute toxicity

Not classified based on available information.

Product:

Acute oral toxicity	: Acute toxicity estimate: > 2,000 mg/kg Method: Calculation method
---------------------	--

Components:**Sitagliptin Phosphate:**

Acute oral toxicity	: LD50 (Rat): > 3,000 mg/kg LD50 (Mouse): 3,000 mg/kg
---------------------	--

Cellulose:

Acute oral toxicity	: LD50 (Rat): > 5,000 mg/kg
Acute inhalation toxicity	: LC50 (Rat): > 5.8 mg/l Exposure time: 4 h Test atmosphere: dust/mist
Acute dermal toxicity	: LD50 (Rabbit): > 2,000 mg/kg

Ertugliflozin:

Ertugliflozin (< 5%) / Sitagliptin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
4.1	11.08.2025	2400339-00016	Date of first issue: 01.02.2018

Acute oral toxicity : LD50 (Rat): 500 mg/kg

Acute inhalation toxicity : Remarks: No data available

Acute dermal toxicity : Remarks: No data available

Magnesium stearate:

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg
Method: OECD Test Guideline 423
Assessment: The substance or mixture has no acute oral toxicity
Remarks: Based on data from similar materials

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg
Remarks: Based on data from similar materials

Propyl 3,4,5-trihydroxybenzoate:

Acute oral toxicity : LD50 (Mouse): 1,700 mg/kg

Acute dermal toxicity : LD50 (Rat): > 2,000 mg/kg
Method: OECD Test Guideline 402
Assessment: The substance or mixture has no acute dermal toxicity

Skin corrosion/irritation

Causes skin irritation.

Components:**Sitagliptin Phosphate:**

Species : Rabbit
Method : Draize Test
Result : No skin irritation

Ertugliflozin:

Result : Corrosive

Magnesium stearate:

Species : Rabbit
Result : No skin irritation
Remarks : Based on data from similar materials

Propyl 3,4,5-trihydroxybenzoate:

Species : reconstructed human epidermis (RhE)
Method : OECD Test Guideline 439

Result : No skin irritation

Ertugliflozin (< 5%) / Sitagliptin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
4.1	11.08.2025	2400339-00016	Date of first issue: 01.02.2018

Serious eye damage/eye irritation

Causes serious eye damage.

Components:**Sitagliptin Phosphate:**

Species	:	Rabbit
Result	:	Irritating to eyes.
Method	:	Draize Test

Ertugliflozin:

Result	:	Severe irritation
--------	---	-------------------

Magnesium stearate:

Species	:	Rabbit
Result	:	No eye irritation
Remarks	:	Based on data from similar materials

Propyl 3,4,5-trihydroxybenzoate:

Species	:	Rabbit
Result	:	Irreversible effects on the eye
Method	:	OECD Test Guideline 405

Respiratory or skin sensitisation**Skin sensitisation**

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Components:**Sitagliptin Phosphate:**

Test Type	:	Local lymph node assay (LLNA)
Species	:	Mouse
Method	:	OECD Test Guideline 429
Result	:	Not a skin sensitizer.

Ertugliflozin:

Test Type	:	Local lymph node assay (LLNA)
Result	:	Not a skin sensitizer.

Magnesium stearate:

Test Type	:	Maximisation Test
Exposure routes	:	Skin contact
Species	:	Guinea pig
Method	:	OECD Test Guideline 406
Result	:	negative

Ertugliflozin (< 5%) / Sitagliptin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
4.1	11.08.2025	2400339-00016	Date of first issue: 01.02.2018

Remarks : Based on data from similar materials

Propyl 3,4,5-trihydroxybenzoate:

Test Type : Local lymph node assay (LLNA)
Exposure routes : Skin contact
Species : Mouse
Result : positive

Assessment : Probability or evidence of skin sensitisation in humans

Chronic toxicity**Germ cell mutagenicity**

Not classified based on available information.

Components:**Sitagliptin Phosphate:**

Genotoxicity in vitro : Test Type: Ames test
Result: negative

Test Type: Chromosome aberration test in vitro
Test system: Chinese hamster ovary cells
Result: negative

Test Type: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro)
Test system: rat hepatocytes
Result: negative

Genotoxicity in vivo : Test Type: Micronucleus test
Species: Mouse
Application Route: Oral
Result: negative

Cellulose:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: In vitro mammalian cell gene mutation test
Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
Species: Mouse
Application Route: Ingestion
Result: negative

Ertugliflozin:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Ertugliflozin (< 5%) / Sitagliptin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
4.1	11.08.2025	2400339-00016	Date of first issue: 01.02.2018

Result: negative

Test Type: Chromosome aberration test in vitro
Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
Species: Rat
Result: negative

Magnesium stearate:

Genotoxicity in vitro : Test Type: In vitro mammalian cell gene mutation test
Result: negative
Remarks: Based on data from similar materials

Test Type: Chromosome aberration test in vitro
Method: OECD Test Guideline 473
Result: negative
Remarks: Based on data from similar materials

Test Type: Bacterial reverse mutation assay (AMES)
Result: negative
Remarks: Based on data from similar materials

Propyl 3,4,5-trihydroxybenzoate:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: In vitro mammalian cell gene mutation test
Result: positive

Test Type: Chromosome aberration test in vitro
Result: positive

Test Type: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro)
Result: negative

Test Type: In vitro sister chromatid exchange assay in mammalian cells
Result: positive

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
Species: Mouse
Application Route: Intraperitoneal injection
Result: negative

Carcinogenicity

Not classified based on available information.

Ertugliflozin (< 5%) / Sitagliptin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
4.1	11.08.2025	2400339-00016	Date of first issue: 01.02.2018

Components:**Sitagliptin Phosphate:**

Species	: Mouse
Application Route	: Oral
Exposure time	: 2 Years
Result	: negative

Species	: Rat
Application Route	: oral (drinking water)
Exposure time	: 2 Years
Result	: positive
Target Organs	: Liver
Remarks	: Significant toxicity observed in testing

Carcinogenicity - Assessment	: Weight of evidence does not support classification as a carcinogen
------------------------------	--

Cellulose:

Species	: Rat
Application Route	: Ingestion
Exposure time	: 72 weeks
Result	: negative

Ertugliflozin:

Species	: Mouse
Application Route	: Oral
Exposure time	: 2 Years
Result	: negative

Species	: Rat
Application Route	: Oral
Exposure time	: 2 Years
Result	: negative

Carcinogenicity - Assessment	: Weight of evidence does not support classification as a carcinogen
------------------------------	--

Propyl 3,4,5-trihydroxybenzoate:

Species	: Rat
Application Route	: Ingestion
Exposure time	: 103 weeks
Result	: negative

Reproductive toxicity

Not classified based on available information.

Components:**Sitagliptin Phosphate:**

Ertugliflozin (< 5%) / Sitagliptin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
4.1	11.08.2025	2400339-00016	Date of first issue: 01.02.2018

Effects on fertility : Test Type: Fertility/early embryonic development
Species: Rat
Application Route: Oral
Fertility: NOAEL Parent: 1,000 mg/kg body weight
Result: Animal testing did not show any effects on fertility.

Effects on foetal development : Test Type: Embryo-foetal development
Species: Rat
Application Route: Oral
Teratogenicity: LOAEL: 250 mg/kg body weight
Result: Embryotoxic effects and adverse effects on the offspring were detected., No teratogenic effects

Test Type: Embryo-foetal development
Species: Rabbit
Teratogenicity: NOAEL: 125 mg/kg body weight
Result: No teratogenic effects

Cellulose:

Effects on fertility : Test Type: One-generation reproduction toxicity study
Species: Rat
Application Route: Ingestion
Result: negative

Effects on foetal development : Test Type: Fertility/early embryonic development
Species: Rat
Application Route: Ingestion
Result: negative

Ertugliflozin:

Effects on fertility : Test Type: Fertility/early embryonic development
Species: Rat
Application Route: Oral
Fertility: NOAEL: 250 mg/kg body weight
Remarks: Maternal toxicity observed.
No significant adverse effects were reported

Test Type: Fertility/early embryonic development
Species: Rabbit
Application Route: Oral
Fertility: NOAEL: 200 mg/kg body weight
Remarks: No significant adverse effects were reported

Effects on foetal development : Test Type: Embryo-foetal development
Species: Rat
Application Route: Oral
Developmental Toxicity: NOAEL: 50 mg/kg body weight
Remarks: Adverse developmental effects were observed

Test Type: Embryo-foetal development
Species: Rabbit

Ertugliflozin (< 5%) / Sitagliptin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
4.1	11.08.2025	2400339-00016	Date of first issue: 01.02.2018

Application Route: Oral
Developmental Toxicity: NOAEL: 250 mg/kg body weight
Remarks: No significant adverse effects were reported

Magnesium stearate:

Effects on fertility : Test Type: Combined repeated dose toxicity study with the reproduction/developmental toxicity screening test
Species: Rat
Application Route: Ingestion
Method: OECD Test Guideline 422
Result: negative
Remarks: Based on data from similar materials

Effects on foetal development : Test Type: Embryo-foetal development
Species: Rat
Application Route: Ingestion
Result: negative
Remarks: Based on data from similar materials

Propyl 3,4,5-trihydroxybenzoate:

Effects on fertility : Test Type: Two-generation reproduction toxicity study
Species: Rat
Application Route: Ingestion
Result: negative

Effects on foetal development : Test Type: Embryo-foetal development
Species: Rat
Application Route: Ingestion
Result: negative

STOT - single exposure

Not classified based on available information.

STOT - repeated exposure

Not classified based on available information.

Components:**Ertugliflozin:**

Exposure routes : Oral
Target Organs : Kidney, Stomach, Prostate
Assessment : May cause damage to organs through prolonged or repeated exposure.

Repeated dose toxicity**Components:****Sitagliptin Phosphate:**

Species : Mouse

Ertugliflozin (< 5%) / Sitagliptin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
4.1	11.08.2025	2400339-00016	Date of first issue: 01.02.2018

NOAEL : 500 mg/kg
LOAEL : 1,000 mg/kg
Application Route : Oral
Exposure time : > 2 yr
Target Organs : Kidney

Species : Rat
NOAEL : 500 mg/kg
LOAEL : 1,000 mg/kg
Application Route : Oral
Exposure time : 14 Weeks
Target Organs : Liver, Kidney, Heart, Teeth

Species : Dog
NOAEL : 10 mg/kg
LOAEL : 50 mg/kg
Application Route : Oral
Exposure time : 53 Weeks
Target Organs : Central nervous system
Symptoms : Loss of balance
Remarks : The mechanism or mode of action may not be relevant in humans.

Species : Dog
NOAEL : 2 mg/kg
LOAEL : 10 mg/kg
Application Route : Oral
Exposure time : 27 Weeks
Target Organs : Skeletal muscle, Central nervous system
Symptoms : Loss of balance
Remarks : The mechanism or mode of action may not be relevant in humans.

Species : Monkey
NOAEL : 100 mg/kg
Application Route : Oral
Exposure time : 14 Weeks
Remarks : No significant adverse effects were reported

Cellulose:

Species : Rat
NOAEL : >= 9,000 mg/kg
Application Route : Ingestion
Exposure time : 90 Days

Ertugliflozin:

Species : Rat
LOAEL : 500 mg/kg
Application Route : Oral
Exposure time : 30 d

Ertugliflozin (< 5%) / Sitagliptin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
4.1	11.08.2025	2400339-00016	Date of first issue: 01.02.2018

Species : Rat
LOAEL : 250 mg/kg
Application Route : Oral
Exposure time : 30 d
Target Organs : Kidney

Species : Rat
LOAEL : 25 mg/kg
Application Route : Oral
Exposure time : 180 d
Target Organs : Kidney, Bone, Stomach

Species : Rat
LOAEL : 25 mg/kg
Exposure time : 90 d
Target Organs : Kidney, Gastrointestinal tract, Prostate

Species : Dog
NOAEL : 150 mg/kg
Application Route : Oral
Exposure time : 270 d
Remarks : No significant adverse effects were reported

Species : Mouse
NOAEL : 100 mg/kg
Application Route : Oral
Exposure time : 90 d
Remarks : No significant adverse effects were reported

Species : Mouse
NOAEL : 100 mg/kg
Application Route : Oral
Exposure time : 28 d
Target Organs : Bone
Remarks : No significant adverse effects were reported

Magnesium stearate:

Species : Rat
NOAEL : > 100 mg/kg
Application Route : Ingestion
Exposure time : 90 Days
Remarks : Based on data from similar materials

Propyl 3,4,5-trihydroxybenzoate:

Species : Rat
NOAEL : 135 mg/kg
Application Route : Ingestion
Exposure time : 13 Weeks

Ertugliflozin (< 5%) / Sitagliptin Formulation

Version 4.1	Revision Date: 11.08.2025	SDS Number: 2400339-00016	Date of last issue: 14.04.2025 Date of first issue: 01.02.2018
----------------	------------------------------	------------------------------	---

Aspiration toxicity

Not classified based on available information.

Experience with human exposure**Components:****Sitagliptin Phosphate:**

Inhalation	: Symptoms: upper respiratory tract infection, pharyngitis, Headache
Ingestion	: Symptoms: upper respiratory tract infection, nasopharyngitis, Headache, Nausea, Abdominal pain, Diarrhoea

Ertugliflozin:

Ingestion	: Symptoms: The most common side effects are:, Headache, constipation, Diarrhoea, Nausea, urinary tract infection, muscle pain, upper respiratory tract infection
-----------	---

SECTION 12. ECOLOGICAL INFORMATION**Ecotoxicity****Components:****Sitagliptin Phosphate:**

Toxicity to fish	: LC50 (Pimephales promelas (fathead minnow)): > 100 mg/l Exposure time: 96 h Method: OECD Test Guideline 203
Toxicity to daphnia and other aquatic invertebrates	: EC50 (Daphnia magna (Water flea)): 60 mg/l Exposure time: 48 h Method: OECD Test Guideline 202
Toxicity to algae/aquatic plants	: EC50 (Pseudokirchneriella subcapitata (green algae)): > 39 mg/l Exposure time: 96 h Method: OECD Test Guideline 201 NOEC (Pseudokirchneriella subcapitata (green algae)): 2.2 mg/l Exposure time: 96 h Method: OECD Test Guideline 201
Toxicity to fish (Chronic toxicity)	: NOEC (Pimephales promelas (fathead minnow)): 9.2 mg/l Exposure time: 33 d Method: OECD Test Guideline 210
Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity)	: NOEC (Daphnia magna (Water flea)): 9.8 mg/l Exposure time: 21 d Method: OECD Test Guideline 211
Toxicity to microorganisms	: EC50: > 150 mg/l Exposure time: 3 h

Ertugliflozin (< 5%) / Sitagliptin Formulation

Version	Revision Date:	SDS Number:	Date of last issue:
4.1	11.08.2025	2400339-00016	14.04.2025
			Date of first issue: 01.02.2018

Test Type: Respiration inhibition
Method: OECD Test Guideline 209

NOEC: 150 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition

Cellulose:

Toxicity to fish : LC50 (*Oryzias latipes* (Japanese medaka)): > 100 mg/l
Exposure time: 48 h
Remarks: Based on data from similar materials

Ertugliflozin:

Toxicity to algae/aquatic plants : EC50 (*Pseudokirchneriella subcapitata* (green algae)): 77 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

NOEC (*Pseudokirchneriella subcapitata* (green algae)): 50 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

Toxicity to fish (Chronic toxicity) : NOEC (*Pimephales promelas* (fathead minnow)): 1 mg/l
Exposure time: 32 d
Method: OECD Test Guideline 210
Remarks: No toxicity at the limit of solubility

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (*Daphnia magna* (Water flea)): 2.14 mg/l
Exposure time: 21 d
Method: OECD Test Guideline 211
Remarks: No toxicity at the limit of solubility

Toxicity to microorganisms : EC50: > 1,000 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

NOEC: 1,000 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

Magnesium stearate:

Toxicity to fish : LC50 (*Leuciscus idus* (Golden orfe)): > 100 mg/l
Exposure time: 48 h
Method: DIN 38412
Remarks: Based on data from similar materials

Toxicity to daphnia and other aquatic invertebrates : EL50 (*Daphnia magna* (Water flea)): > 1 mg/l
Exposure time: 47 h

Ertugliflozin (< 5%) / Sitagliptin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
4.1	11.08.2025	2400339-00016	Date of first issue: 01.02.2018

Test substance: Water Accommodated Fraction
 Method: Directive 67/548/EEC, Annex V, C.2.
 Remarks: Based on data from similar materials
 No toxicity at the limit of solubility

Toxicity to algae/aquatic plants	:	EL50 (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l Exposure time: 72 h Test substance: Water Accommodated Fraction Method: OECD Test Guideline 201 Remarks: Based on data from similar materials No toxicity at the limit of solubility NOELR (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l Exposure time: 72 h Test substance: Water Accommodated Fraction Method: OECD Test Guideline 201 Remarks: Based on data from similar materials
Toxicity to microorganisms	:	EC10 (Pseudomonas putida): > 100 mg/l Exposure time: 16 h Test substance: Water Accommodated Fraction Remarks: Based on data from similar materials

Propyl 3,4,5-trihydroxybenzoate:

Toxicity to daphnia and other aquatic invertebrates	:	EC50 (Daphnia magna (Water flea)): 19.6 mg/l Exposure time: 48 h Test substance: Neutralised product Method: OECD Test Guideline 202 Remarks: The test was conducted according to guideline
Toxicity to algae/aquatic plants	:	ErC50 (Pseudokirchneriella subcapitata (green algae)): 0.22 mg/l Exposure time: 72 h Test substance: Neutralised product Method: OECD Test Guideline 201 Remarks: The test was conducted according to guideline EC10 (Pseudokirchneriella subcapitata (green algae)): 0.096 mg/l Exposure time: 72 h Test substance: Neutralised product Method: OECD Test Guideline 201 Remarks: The test was conducted according to guideline
Toxicity to microorganisms	:	EC50 (activated sludge): 636 mg/l Exposure time: 3 h Method: OECD Test Guideline 209

Ertugliflozin (< 5%) / Sitagliptin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
4.1	11.08.2025	2400339-00016	Date of first issue: 01.02.2018

Persistence and degradability**Components:****Sitagliptin Phosphate:**

Biodegradability	:	Result: not rapidly degradable Biodegradation: 39.7 % Exposure time: 28 d Method: OECD Test Guideline 314
Stability in water	:	Hydrolysis: 50 %(401 d) Method: OECD Test Guideline 111

Cellulose:

Biodegradability	:	Result: Readily biodegradable.
------------------	---	--------------------------------

Ertugliflozin:

Biodegradability	:	Result: Not readily biodegradable. Biodegradation: 40.8 % Exposure time: 28 d
------------------	---	---

Magnesium stearate:

Biodegradability	:	Result: Not biodegradable Remarks: Based on data from similar materials
------------------	---	--

Propyl 3,4,5-trihydroxybenzoate:

Biodegradability	:	Result: Not readily biodegradable. Biodegradation: 49.4 % Exposure time: 28 d Method: OECD Test Guideline 301F
------------------	---	---

Bioaccumulative potential**Components:****Sitagliptin Phosphate:**

Partition coefficient: n-octanol/water	:	log Pow: -0.03
--	---	----------------

Ertugliflozin:

Partition coefficient: n-octanol/water	:	log Pow: 2.47
--	---	---------------

Magnesium stearate:

Partition coefficient: n-octanol/water	:	log Pow: > 4
--	---	--------------

Propyl 3,4,5-trihydroxybenzoate:

Partition coefficient: n-octanol/water	:	log Pow: 1.8 Remarks: Calculation
--	---	--------------------------------------

Ertugliflozin (< 5%) / Sitagliptin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
4.1	11.08.2025	2400339-00016	Date of first issue: 01.02.2018

Mobility in soil**Components:****Sitagliptin Phosphate:**

Distribution among environmental compartments : log K_{oc}: 4.37

Ertugliflozin:

Distribution among environmental compartments : log K_{oc}: 2.88

Other adverse effects

No data available

SECTION 13. DISPOSAL CONSIDERATIONS**Disposal methods**

Waste from residues	:	Do not dispose of waste into sewer. Dispose of in accordance with local regulations.
Contaminated packaging	:	Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION**International Regulations****UNRTDG**

UN number	:	Not applicable
Proper shipping name	:	Not applicable
Class	:	Not applicable
Subsidiary risk	:	Not applicable
Packing group	:	Not applicable
Labels	:	Not applicable
Environmentally hazardous	:	no

IATA-DGR

UN/ID No.	:	Not applicable
Proper shipping name	:	Not applicable
Class	:	Not applicable
Subsidiary risk	:	Not applicable
Packing group	:	Not applicable
Labels	:	Not applicable
Packing instruction (cargo aircraft)	:	Not applicable
Packing instruction (passenger aircraft)	:	Not applicable

IMDG-Code

UN number	:	Not applicable
Proper shipping name	:	Not applicable

Ertugliflozin (< 5%) / Sitagliptin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
4.1	11.08.2025	2400339-00016	Date of first issue: 01.02.2018

Class	: Not applicable
Subsidiary risk	: Not applicable
Packing group	: Not applicable
Labels	: Not applicable
EmS Code	: Not applicable
Marine pollutant	: Not applicable

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

National Regulations**ADG**

UN number	: Not applicable
Proper shipping name	: Not applicable
Class	: Not applicable
Subsidiary risk	: Not applicable
Packing group	: Not applicable
Labels	: Not applicable
Hazchem Code	: Not applicable

Special precautions for user

Not applicable

SECTION 15. REGULATORY INFORMATION**Safety, health and environmental regulations/legislation specific for the substance or mixture**

Therapeutic Goods (Poisons Standard) Instrument	: Schedule 5 (Please use the original publication to check for specific uses, specific conditions or threshold limits that might apply for this chemical)
---	---

Prohibition/Licensing Requirements	: There is no applicable prohibition, authorisation and restricted use requirements, including for carcinogens referred to in Schedule 10 of the model WHS Act and Regulations.
------------------------------------	---

The components of this product are reported in the following inventories:

AICS	: not determined
------	------------------

DSL	: not determined
-----	------------------

IECSC	: not determined
-------	------------------

SECTION 16: ANY OTHER RELEVANT INFORMATION**Further information**

Revision Date	: 11.08.2025
Sources of key data used to compile the Safety Data	: Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen-

Ertugliflozin (< 5%) / Sitagliptin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
4.1	11.08.2025	2400339-00016	Date of first issue: 01.02.2018

Sheet cy, <http://echa.europa.eu/>

Date format : dd.mm.yyyy

Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)
AU OEL : Australia. Workplace Exposure Standards for Airborne Contaminants.

ACGIH / TWA : 8-hour, time-weighted average
AU OEL / TWA : Exposure standard - time weighted average

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

SAFETY DATA SHEET



Ertugliflozin (< 5%) / Sitagliptin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
4.1	11.08.2025	2400339-00016	Date of first issue: 01.02.2018

AU / EN